broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K63504947-001-14-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.676659 | 1.568037 | 0.124099 | 0.967622 | 4.426214 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000939 |
BRD-K63712959-001-01-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.166988 | 3.606117 | 0.322064 | 1 | 0.014414 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000939 |
BRD-K64052750-001-22-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.840097 | -0.134878 | 0.016265 | 0.888783 | 43.834903 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000939 |
BRD-K64881305-001-03-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.316711 | 6.273196 | 0.688836 | 0.474521 | 0.005738 | 0.006733 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000939 |
BRD-K66175015-001-12-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.001113 | 0.664361 | 0.696772 | 0.672222 | 0.492389 | 0.494051 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000939 |
BRD-K67844266-003-01-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.356734 | 1.060392 | 0.547607 | 0.758878 | 0.268077 | 0.871303 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000939 |
BRD-K69001009-001-02-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.914533 | -4.490998 | 0.040419 | 0.932756 | 1.262892 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000939 |
BRD-K69694239-001-02-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.178108 | 7.493815 | 0.789385 | 0.728529 | 0.405408 | 0.429947 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000939 |
BRD-K69776681-001-03-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.229493 | 3.583911 | 0.83329 | 0.539998 | 0.030464 | 0.03616 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000939 |
BRD-K70301465-001-05-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.731837 | 0.391573 | -0.028502 | 0.95861 | 16.03649 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000939 |
BRD-K70401845-001-15-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.861861 | -1.040909 | 0.077986 | 0.977568 | 0.002398 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000939 |
BRD-K73838513-003-05-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.471161 | 2.796153 | 0.401269 | 0.906033 | 1.788004 | 4.959903 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000939 |
BRD-K74514084-003-09-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.50725 | 1.362958 | 0.404799 | 0.909703 | 1.808014 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000939 |
BRD-K75009076-001-02-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.155442 | 1.324734 | 0.736992 | 0.622612 | 0.13106 | 0.173594 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000939 |
BRD-K76210423-001-01-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.962516 | -0.463946 | 0.015184 | 0.984691 | 0.025832 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000939 |
BRD-K76239644-001-02-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.665033 | 0.005366 | -0.094267 | 0.833483 | 0.670979 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000939 |
BRD-K76674262-001-03-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.093274 | 1.053295 | 0.918175 | 0.401443 | 0.016043 | 0.019517 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000939 |
BRD-K76908866-001-07-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.807613 | 0.682299 | -0.000067 | 0.839435 | 0.001682 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000939 |
BRD-K77625799-001-07-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.473155 | -0.734961 | 0.075749 | 0.956795 | 0.000447 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000939 |
BRD-K78431006-001-15-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -5.353383 | 6.64366 | 0.202149 | 0.99398 | 15.161021 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000939 |
BRD-K79254416-001-21-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.689709 | 108.257382 | 0.211144 | 0.913932 | 0.677558 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000939 |
BRD-K81016934-001-02-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.98164 | 0.032947 | 0.000615 | 0.990597 | 0.017793 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000939 |
BRD-K81418486-001-44-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.705472 | -2.543431 | 0.150496 | 0.974231 | 0.001359 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000939 |
BRD-K81473043-001-19-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.096698 | 5.249244 | 0.807454 | 0.841144 | 0.113408 | 0.118147 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000939 |
BRD-K82135108-001-04-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.327254 | 1.356358 | 0.716208 | 0.804784 | 0.034016 | 0.07447 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000939 |
BRD-K82746043-001-19-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.206678 | 1.984901 | 0.159065 | 1 | 0.025161 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000939 |
BRD-K82818427-001-04-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.952644 | -0.032015 | -0.000641 | 0.966258 | 169,323,867,049.6069 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000939 |
BRD-K83029223-001-01-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.304019 | 7.043823 | 0.741053 | 0.56853 | 0.001523 | 0.00174 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000939 |
BRD-K83988098-001-02-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.098959 | 2.680345 | 0.864683 | 0.793767 | 0.01694 | 0.018393 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000939 |
BRD-K85402309-043-01-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.197749 | 4.358658 | 0.822169 | 0.928559 | 1.202983 | 1.350249 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000939 |
BRD-K86118762-001-01-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.879042 | -1.418473 | 0.179396 | 0.917092 | 0.47669 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000939 |
BRD-K86972824-001-01-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.700933 | 2.90419 | 0.228301 | 0.943426 | 1.597529 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000939 |
BRD-K87737963-001-06-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.608726 | 0.067457 | 0.051897 | 0.827932 | 2.919369 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000939 |
BRD-K87782578-001-01-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.781419 | -0.515868 | -0.189831 | 0.888088 | 0.089582 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000939 |
BRD-K87909389-003-03-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.222554 | 2.829424 | 0.856361 | 0.594723 | 0.063521 | 0.07822 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000939 |
BRD-K88510285-001-17-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.157749 | 1.863668 | 0.853415 | 0.555107 | 0.014873 | 0.018227 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000939 |
BRD-K89014967-001-04-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.788331 | -4.003985 | 0.177528 | 0.845399 | 0.730598 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000939 |
BRD-K92441787-001-04-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.806692 | -2.989417 | 0.033493 | 0.851549 | 1.052339 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000939 |
BRD-K92723993-001-17-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.451043 | 0.613583 | 0.11795 | 1 | 10.955911 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000939 |
BRD-K95142244-001-01-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -0.015656 | 0.348884 | 0.83914 | 0.488063 | 0.073777 | 0.067536 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000939 |
BRD-K96123349-236-02-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.813273 | 0.331984 | 0.033299 | 0.89593 | 0.033815 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000939 |
BRD-K98572433-001-02-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.815797 | 2.401265 | 0.090849 | 0.858816 | 0.005873 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000939 |
BRD-K99113996-001-02-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.269787 | 1.885593 | 0.911414 | 0.792122 | 0.633029 | 0.955129 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000939 |
BRD-K99749624-001-07-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.777608 | -0.310945 | -0.047294 | 0.861026 | 0.540633 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000939 |
BRD-M97302542-001-04-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.755268 | -0.013038 | -0.032675 | 0.87596 | 0.637063 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000939 |
BRD-A25234499-001-19-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.059166 | 0.086093 | -0.008763 | 1 | 0.000295 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000940 |
BRD-A70858459-001-01-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.573974 | -1.114792 | -0.041534 | 0.944999 | 0.001655 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000940 |
BRD-A74914197-001-02-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.717751 | 6.308445 | 0.582915 | 0.823378 | 0.00144 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000940 |
BRD-K02113016-001-19-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.703472 | 2.760943 | 0.121 | 0.883159 | 0.218425 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000940 |
BRD-K02130563-001-11-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.236537 | 0.989197 | 0.624958 | 0.461608 | 0.010038 | 0.019183 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000940 |
BRD-K03390685-001-01-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.352317 | 5.072709 | 0.479612 | 0.879962 | 1.655329 | 2.105213 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000940 |
BRD-K03406345-001-21-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.053256 | -0.391727 | -0.002945 | 1 | 0.44966 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000940 |
BRD-K03449891-001-08-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.08467 | 1.707679 | 0.77227 | 0.692912 | 0.386347 | 0.430685 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000940 |
BRD-K03765900-001-01-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.155657 | 0.721788 | 0.71735 | 0.571775 | 0.072539 | 0.121614 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000940 |
BRD-K05804044-001-18-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.19897 | 0.756745 | 0.701852 | 0.576875 | 0.058539 | 0.114458 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000940 |
BRD-K06814349-304-02-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.300223 | 3.726262 | 0.722758 | 0.799073 | 0.616375 | 0.78844 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000940 |
BRD-K08109215-001-06-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.840963 | -0.800443 | -0.021941 | 0.930208 | 0.042039 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000940 |
BRD-K08542803-001-02-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.054885 | 0.657633 | 0.594576 | 0.543015 | 0.092914 | 0.110884 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000940 |
BRD-K08547377-001-04-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.624859 | 3.523725 | -0.06131 | 0.719227 | 0.007007 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000940 |
BRD-K08703257-001-13-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.200043 | 0.228831 | -0.061021 | 1 | 0.002544 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000940 |
BRD-K08799216-001-05-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | -0.122234 | 1.278542 | 0.354551 | 0.907062 | 6.330341 | 5.335024 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000940 |
BRD-K09951645-001-11-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.646002 | 0.034765 | 0.028681 | 0.825789 | 0.193706 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000940 |
BRD-K11630072-001-13-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.536143 | 0.130651 | 0.057018 | 0.773083 | 0.109928 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000940 |
BRD-K12343256-001-14-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.407969 | 2.01808 | 0.790686 | 0.579757 | 0.010176 | 0.023539 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000940 |
BRD-K13049116-001-04-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.382501 | 3.297513 | 0.516197 | 0.838428 | 0.789307 | 1.224549 | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000940 |
BRD-K13390322-001-06-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.100312 | 7.648791 | 0.900731 | 0.605449 | 0.141804 | 0.146017 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000940 |
BRD-K13514097-001-04-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | -0.042246 | 0.047039 | 0.192777 | 0.379495 | 0.000021 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000940 |
BRD-K13662825-001-07-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.020223 | 0.503331 | 0.711459 | 0.463047 | 0.011217 | 0.012176 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000940 |
BRD-K14109347-001-03-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.965155 | -0.030405 | -0.003278 | 0.980409 | 296.937287 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000940 |
BRD-K15179879-001-03-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.193677 | 3.716247 | 0.821591 | 0.469727 | 0.016914 | 0.019298 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000940 |
BRD-K15600710-066-05-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.223141 | 11.998245 | 0.784264 | 0.721425 | 0.302486 | 0.317761 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000940 |
BRD-K16730910-001-10-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.132186 | 0.843327 | 0.651481 | 0.683684 | 0.307383 | 0.442378 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000940 |
BRD-K17555800-003-02-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.829379 | -0.055571 | -0.05191 | 0.897959 | 103.907512 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000940 |
BRD-K17610631-001-03-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.219665 | 4.752698 | 0.906265 | 0.690893 | 0.207318 | 0.234159 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000940 |
BRD-K17743125-001-08-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.102583 | 1.798788 | 0.643079 | 0.850916 | 2.058246 | 2.338469 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000940 |
BRD-K17894950-001-14-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.093758 | -0.042703 | -0.010032 | 1 | 6.425864 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000940 |
BRD-K18961567-001-01-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.164044 | 4.174387 | 0.708417 | 0.862601 | 2.02956 | 2.232392 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000940 |
BRD-K19540840-001-09-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.336919 | 2.814949 | 0.40778 | 0.950688 | 5.107945 | 7.605014 | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000940 |
BRD-K19687926-001-04-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.853564 | 2.402204 | 0.159836 | 0.879539 | 0.003389 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000940 |
BRD-K19796430-001-05-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.212472 | 0.052788 | -0.024474 | 1 | 0.064258 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000940 |
BRD-K22064724-001-01-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.133457 | 2.147433 | 0.753186 | 0.598007 | 0.110868 | 0.128116 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000940 |
BRD-K22822991-001-02-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.001906 | 0.617263 | -0.067513 | 1 | 0.178092 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000940 |
BRD-K23228615-001-02-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.070423 | 1.126278 | 0.873745 | 0.556718 | 0.097951 | 0.112083 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000940 |
BRD-K23984367-001-07-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.299458 | 3.742099 | 0.705556 | 0.795242 | 0.586298 | 0.748416 | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000940 |
BRD-K26026438-001-01-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.532082 | 0.376412 | 0.055598 | 0.794807 | 0.17889 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000940 |
BRD-K26657438-001-15-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.022745 | 0.115127 | -0.001399 | 1 | 0.000113 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000940 |
BRD-K28822270-001-03-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.17114 | 1.702933 | 0.687998 | 0.763291 | 0.658317 | 0.841944 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000940 |
BRD-K29905972-001-06-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.208958 | 0.327359 | 0.320281 | 0.601892 | 0.074439 | 0.388788 | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000940 |
BRD-K30577245-001-05-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.163254 | 0.751826 | 0.750661 | 0.398616 | 0.00049 | 0.000829 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000940 |
BRD-K31698212-001-02-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.246191 | -0.269875 | 0.051091 | 1 | 0.105584 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000940 |
BRD-K31928526-001-02-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.515137 | 3.858604 | 0.815818 | 0.703476 | 0.026452 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000940 |
BRD-K33379087-001-07-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.276366 | 2.543075 | 0.69449 | 0.7278 | 0.259798 | 0.356484 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000940 |
BRD-K33610132-001-02-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.284409 | 0.892761 | 0.3639 | 0.801955 | 0.756843 | 1.941921 | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000940 |
BRD-K33622447-066-01-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.277878 | 1.543732 | 0.507157 | 0.847527 | 1.325095 | 2.241402 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000940 |
BRD-K35520305-001-16-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.599125 | -0.08783 | -0.088566 | 0.81304 | 0.016468 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000940 |
BRD-K36627727-001-05-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.623432 | -0.893788 | -0.070558 | 0.889334 | 0.009671 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000940 |
BRD-K36788280-001-01-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | -0.529473 | -1.418566 | -0.029189 | 0.978971 | 0.000202 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000940 |
BRD-K37379014-001-02-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.706707 | 0.412765 | 0.109706 | 0.869659 | 0.002479 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000940 |
BRD-K38332599-001-01-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.130056 | 0.842174 | 0.831767 | 0.575883 | 0.088523 | 0.126594 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000940 |
BRD-K38527262-300-01-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.862397 | -4.125499 | 0.287497 | 0.914167 | 0.100675 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000940 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.